A new RNA-based therapy aims to address one of cardiology’s most persistent challenges: the heart’s inability to regenerate after injury.
A randomized trial finds weekly extended-release buprenorphine yields neonatal outcomes comparable to sublingual treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results